Table 3.

Association of the frequency of pulmonary infection during the prevaccine period, chronic respiratory failure, pneumococcal polysaccharide vaccine 23, gender and age with the first episode of pulmonary infection or death of any cause

	HR (95% CI)	p Value
Covariates for the risk of the first episode of pulmonary infection
Pulmonary infection during the prevaccine period
1 episode	3.251* (2.436 to 4.338)	<0.001
>1 episode	6.480* (4.380 to 9.589)	<0.001
Chronic respiratory failure	1.767 (1.227 to 2.546)	0.002
Pneumococcal polysaccharide vaccine 23 vaccination	1.096 (0.848 to 1.416)	0.396
Gender	0.911 (0.712 to 1.166)	0.457
Age	0.994 (0.976 to 1.013)	0.553
Covariates for the risk of death of any cause
Pulmonary infection during the prevaccine period
1 episode	2.289* (1.380 to 3.797)	0.001
>1 episode	3.134* (1.486 to 6.612)	0.003
Chronic respiratory failure	2.152 (1.234 to 3.752)	0.007
Pneumococcal polysaccharide vaccine 23 vaccination	0.795 (0.499 to 1.264)	0.332
Gender	0.340 (0.199 to 0.580)	<0.001
Age	1.040 (1.008 to 1.072)	0.014

^*HR was estimated in relation to the case of outpatients with no episode of pulmonary infection during the prevaccine period.